RTsafe and OSL sign an exclusive agreement for distribution
14th February 2025
RTsafe, a medical technology company focused on improving the safety and accuracy of radiotherapy for cancer and other medical conditions, announces that Oncology Systems Limited (OSL) will be the exclusive distributor of RTsafe’s products and services in the UK and Ireland.
We are delighted to announce this new collaboration with a major and trusted independent medical equipment and software provider to the NHS and private hospitals. Our innovative anthropomorphic dosimetry phantoms are designed to ensure the highest levels of safety and precision in radiotherapy.
“OSL is delighted to partner with RTsafe, whose fully customisable anthropomorphic phantoms and dosimetry services bring unparalleled clinical relevance and precision to patient specific QA, as well as technique development, commissioning, and audit. I look forward to this partnership opening up access to RTsafe’s cutting edge equipment and services to all UK and Irish departments, bringing with it great benefits in treatment safety and accuracy”, adds Rob Julian, Science and Innovation Lead at OSL.
About OSL
Established in 1999, Oncology Systems Limited is based in Shrewsbury, England, UK.
Since then, OSL has developed to become a trusted independent provider of medical equipment and software to the NHS and private hospitals in the UK and Ireland.
For more information, visit www.osl.uk.com
About RTsafe
RTsafe is a medical technology company that has developed a unique approach to quality assurance that significantly enhances the safety and accuracy of radiotherapy for cancer and other medical conditions. It combines proven expertise in medical physics with highly accurate 3D printing technology to create pseudo‐in‐vivo dosimetry phantoms towards End‐to‐End commissioning, benchmarking and patient‐specific quality assurance in SRS, IMRT, VMAT and SBRT applications. The anatomically accurate effigies enable medical professionals to plan more precise treatment interventions for each individual patient and help radiotherapy technology innovators to fine‐tune their products. The result is more effective individualized therapy and reduced patient risk.
For more information, visit www.rt-safe.com.
